With Wyeth, Pfizer Becomes The Second-largest Multinational Pharma In India
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth India had revenues of $76 million in 2008 from products such as Enbrel, Rapamune, Prevenar and Tygacil.
You may also be interested in...
Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment
One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S
The Politics Of Mega-Mergers: Health Care Reform And U.S. Biopharma Realignment
Merck/Schering, Pfizer/Wyeth underscore sense of long-term structural change in U.S. pharma market.
The Politics Of Mega-Mergers: Health Care Reform And U.S. Biopharma Realignment
Merck/Schering, Pfizer/Wyeth underscore sense of long-term structural change in U.S. pharma market.